<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541914</url>
  </required_header>
  <id_info>
    <org_study_id>20030871109</org_study_id>
    <nct_id>NCT04541914</nct_id>
  </id_info>
  <brief_title>Diagnostic Efficacy of Molecular Diagnostic Method for AMR in ABOiKT</brief_title>
  <official_title>Diagnostic Efficacy of Peripheral Blood Marker-based Molecular Diagnostic Method for Antibody-mediated Rejection (AMR) in ABO Blood Type Incompatible Kidney Transplant (ABOiKT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the peripheral blood marker-based molecular&#xD;
      diagnostic method developed in the previous study can differentiate and predict accommodation&#xD;
      and antibody-mediated rejection (AMR) in ABO blood type incompatible kidney transplant&#xD;
      (ABOiKT) patients who are prospectively recruited.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our research team retrospectively analyzes biomarkers that distinguish accommodation and&#xD;
      acute antibody-mediated rejection through transcriptomic analysis of peripheral blood in&#xD;
      patients with ABO blood type incompatibility kidney transplantation at Seoul National&#xD;
      University Hospital. Through this, a classification model was developed to distinguish&#xD;
      accommodation and antibody-mediated rejection using peripheral blood marker at the time of&#xD;
      the protocol biopsy on the 10th day after renal transplantation, and recently reported as a&#xD;
      new peripheral blood marker-based molecular diagnostic method. On the 10th day after surgery,&#xD;
      transcriptomic analysis through RNA-seq was performed using samples of peripheral blood from&#xD;
      18 patients with accommodation and 10 patients with antibody-mediated rejection confirmed by&#xD;
      protocol biopsy. The candidate genes were validated in the discovery set and another&#xD;
      independent training set through quantitative real-time polymerase chain reaction (PCR).&#xD;
      Finally, a 5-gene classification model including COX7A2L, CD69, CD14, CFD, and FOXJ3 was&#xD;
      developed through logistic regression analysis.&#xD;
&#xD;
      To evaluate the diagnostic effectiveness (sensitivity, specificity) for the peripheral blood&#xD;
      marker-based molecular diagnostic method by prospectively recruiting patients with ABO blood&#xD;
      type incompatible kidney transplantation is needed. And, it is necessary to evaluate the&#xD;
      effectiveness of whether the peripheral blood marker-based molecular diagnostic method can&#xD;
      predict antibody-mediated rejection or accommodation as a result of protocol biopsy that will&#xD;
      be performed on the 10th day after transplantation - peripheral blood samples collected&#xD;
      earlier than the 10th day (day 5 and day 7) after ABO blood type incompatible kidney&#xD;
      transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The value by logistic regression equation using peripheral blood marker on the 7th day after ABOiKT for prediction of antibody-mediated rejection</measure>
    <time_frame>the 7th day after ABO-incompatible kidney transplantation</time_frame>
    <description>To evaluate whether the value by logistic regression equation using peripheral blood marker-based molecular diagnostic method on the 7th day after ABOiKT can predict antibody-mediated rejection from the protocol kidney biopsy results on the 10±2 day after ABOiKT (If the probability value of a sample is higher than 0.5, it is classified as accommodation. Samples with values &lt;0.5 are classified as antibody-mediated rejection by this diagnostic method)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The value by logistic regression equation using peripheral blood marker on the 5th or 10th day after ABOiKT for prediction of antibody-mediated rejection</measure>
    <time_frame>the 5th or 10th day after ABO-incompatible kidney transplantation</time_frame>
    <description>To evaluate whether the value by logistic regression equation using peripheral blood marker-based molecular diagnostic method on the 5th or 10th day after ABOiKT can predict antibody-mediated rejection from the protocol kidney biopsy results on the 10±2 day after ABOiKT (If the probability value of a sample is higher than 0.5, it is classified as accommodation. Samples with values &lt;0.5 are classified as antibody-mediated rejection by this diagnostic method)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>ABO Blood Type Incompatible Kidney Transplantation</condition>
  <condition>Antibody-mediated Rejection</condition>
  <arm_group>
    <arm_group_label>Validation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation for diagnostic efficacy of peripheral blood marker-based molecular diagnostic method for antibody-mediated rejection (AMR) in ABO blood type incompatible kidney transplant (ABOiKT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>5-gene classification model</intervention_name>
    <description>Peripheral blood marker-based molecular diagnostic method for AMR in ABOiKT</description>
    <arm_group_label>Validation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ABO blood group incompatible kidney transplant patients&#xD;
&#xD;
          -  Patients who consent to written consent&#xD;
&#xD;
          -  Patients over 19 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Patients with a history of drug abuse within the last 6 months&#xD;
&#xD;
          -  Psychiatric disease history (major depression, bipolar disorder, schizophrenia, etc.)&#xD;
&#xD;
          -  Patients who do not want to participate in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaeseok Yang, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transplantation Center, Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaeseok Yang, M.D., Ph.D</last_name>
    <phone>+82-2-2072-4128</phone>
    <email>jcyjs@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaeseok Yang, M.D., Ph.D.</last_name>
      <phone>82-2-2072-4128</phone>
      <email>jcyjs@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Tai Yeon Koo, M.D., Ph.D.</last_name>
      <phone>82-2-2072-4014</phone>
      <email>marvin77@empas.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Jeon HJ, Lee JG, Kim K, Jang JY, Han SW, Choi J, Ryu JH, Koo TY, Jeong JC, Lee JW, Ishida H, Park JB, Lee SH, Ahn C, Yang J. Peripheral blood transcriptome analysis and development of classification model for diagnosing antibody-mediated rejection vs accommodation in ABO-incompatible kidney transplant. Am J Transplant. 2020 Jan;20(1):112-124. doi: 10.1111/ajt.15553. Epub 2019 Aug 26.</citation>
    <PMID>31373158</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jaeseok Yang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>molecular diagnostic method</keyword>
  <keyword>diagnostic efficacy</keyword>
  <keyword>accommodation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

